The 2014 National Rx Drug Abuse Summit – held April 22-24, 2014, at the Atlanta Marriott Marquis in Atlanta, Georgia – drew approximately 1,100 participants from 46 states, the District of Columbia, Canada and New Zealand to focus on ways we can all Make an Impact in the fight against prescription drug abuse.
Conference programming featured thought-providing presentations by 147 experts and leaders in seven Educational Track focus areas tailored to provide stakeholders timely and relevant information for their particular field: Clinical, Education & Advocacy, Law Enforcement, Pharmacy, Prescription Drug Monitoring Programs, Third-Party Payer, and Treatment.
Keynote speakers included: actress Melanie Griffith; U.S. Representatives Bill Keating (D-MA), Stephen Lynch (D-MA), Tom Price (R-GA), Nick Rahall (D-WV), Harold “Hal” Rogers (R-KY), and former Congresswoman Mary Bono; Governors Steve Beshear (D-KY) and Nathan Deal (R-GA); Michael Botticelli, Acting Director of the White House Office of National Drug Control Policy (ONDCP); Dr. Francis Collins, Director of the National Institutes of Health (NIH); Dr. Margaret Hamburg, Commissioner of the U.S. Food and Drug Administration (FDA); Dr. Thomas Frieden, Director of the Centers for Disease Control (CDC); Dr. Elinore McCance-Katz, Chief Medical Officer of the Substance Abuse and Mental Health Services Administration (SAMSHA); Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA); and State Attorneys General Jack Conway (D-KY), Sam Olens (R-GA), and Greg Zoeller (R-IN).
- Listen to audio recordings of the Breakout sessions, watch videos of the General Session programs, and download copies of the PowerPoint presentations. Click here.
- View photos from 2014 Summit events. Click here.
- View a listing of the 2014 Session Presenters. Click here.
Conference attendees included: Federal and state legislators and policy makers; federal and state executive leaders; health care practitioners; pharmacists; certified substance abuse counselors and recovery specialists; law enforcement personnel; treatment facility managers; advocates, families, and patients working to increase awareness and effect change; pharmaceutical executives; prominent academicians and researchers; government officials tasked with regulatory oversight; insurance payers and benefits managers; and suppliers of prescription monitoring technologies.